Cite
MLA Citation
Hans Wildiers et al.. “Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.” Breast, vol. 64, 2022, pp. 100–111. http://access.bl.uk/ark:/81055/vdc_100158012670.0x00003d